The effect of brolucizumab on diabetic macular edema and ischemia; a real-world analysis
Objective - The response to intravitreal brolucizumab on diabetic macular edema (DME) and macular ischemia was studied in treatment-refractory and treatment-naïve patients. - Methods - Patients with either recalcitrant (group 1) or treatment-naïve (group 2) DME were studied before and after intrav...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 21, 2025
|
| In: |
European journal of ophthalmology
Year: 2025, Jahrgang: 35, Heft: 6, Pages: 2174-2183 |
| ISSN: | 1724-6016 |
| DOI: | 10.1177/11206721251340436 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1177/11206721251340436 Verlag, kostenfrei, Volltext: https://journals.sagepub.com/doi/10.1177/11206721251340436 
|
| Verfasserangaben: | Argyrios Chronopoulos, Lourdes Vidal-Oliver, Lea K. Sas, Jakob W. Holzwarth, James Schutz and Lars-Olof Hattenbach |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1935171062 | ||
| 003 | DE-627 | ||
| 005 | 20260205170139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250902s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/11206721251340436 |2 doi | |
| 035 | |a (DE-627)1935171062 | ||
| 035 | |a (DE-599)KXP1935171062 | ||
| 035 | |a (OCoLC)1559705104 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Chronopoulos, Argyrios |d 1979- |e VerfasserIn |0 (DE-588)136184626 |0 (DE-627)577702262 |0 (DE-576)300882106 |4 aut | |
| 245 | 1 | 4 | |a The effect of brolucizumab on diabetic macular edema and ischemia; a real-world analysis |c Argyrios Chronopoulos, Lourdes Vidal-Oliver, Lea K. Sas, Jakob W. Holzwarth, James Schutz and Lars-Olof Hattenbach |
| 264 | 1 | |c May 21, 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.09.2025 | ||
| 520 | |a Objective - The response to intravitreal brolucizumab on diabetic macular edema (DME) and macular ischemia was studied in treatment-refractory and treatment-naïve patients. - Methods - Patients with either recalcitrant (group 1) or treatment-naïve (group 2) DME were studied before and after intravitreal brolucizumab. All patients underwent a comprehensive ophthalmological examination including optical coherence tomography (OCT) and OCT-angiography (OCT-A). We compared the DME and macular/choriocapillaris ischemia before and after the loading dose. - Results - A total of 33 eyes of 26 patients were examined. 18 eyes were switched to brolucizumab, 15 eyes were treatment naive. All eyes responded with anatomical and functional improvement: group 1: 391 vs 298 μm (p = 0.005), 0.6 ± 0.4 logMAR vs. 0.4 ± 0.4 logMAR) (p = 0.01), group 2: 430 vs 281 μm (p = 0.0007), 0.5 ± 0.2 logMAR vs. 0.2 ± 0.2 logMAR (p = 0.004). In group 2 there was also significant improvement in retinal vascular parameters, especially in the central and inner circles of the ETDRS grid: central capillary density 6.55 vs 9.03 mm/mm2 (p = 0.008), inner 11.2 vs 13, 9 mm/mm2 (p = 0.02), central perfusion density 15.5% vs 20.7% (p = 0.02). Choriocapillaris flow deficit (CCFD%) also improved after the loading dose (40.3 vs. 35.3, p = 0.03). Although not statistically significant, there was also an improved foveal circularity. - Conclusion - Intravitreal brolucizumab leads to significant functional and anatomical improvement in diabetic macular edema and has also a beneficial effect on macular ischemia as shown by improvement in both retinal and choroidal perfusion. | ||
| 700 | 1 | |a Vidal-Oliver, Lourdes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sas, Lea K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Holzwarth, Jakob |d 1987- |e VerfasserIn |0 (DE-588)1234496291 |0 (DE-627)1759327565 |4 aut | |
| 700 | 1 | |a Schutz, James |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hattenbach, Lars-Olof |e VerfasserIn |0 (DE-588)1135612463 |0 (DE-627)890550832 |0 (DE-576)489878571 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of ophthalmology |d Thousand Oaks, CA : Sage Publishing, 1991 |g 35(2025), 6, Seite 2174-2183 |h Online-Ressource |w (DE-627)269534601 |w (DE-600)1475018-1 |w (DE-576)47295234X |x 1724-6016 |7 nnas |a The effect of brolucizumab on diabetic macular edema and ischemia; a real-world analysis |
| 773 | 1 | 8 | |g volume:35 |g year:2025 |g number:6 |g pages:2174-2183 |g extent:10 |a The effect of brolucizumab on diabetic macular edema and ischemia; a real-world analysis |
| 856 | 4 | 0 | |u https://doi.org/10.1177/11206721251340436 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://journals.sagepub.com/doi/10.1177/11206721251340436 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20250902 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1234496291 |a Holzwarth, Jakob |m 1234496291:Holzwarth, Jakob |d 60000 |e 60000PH1234496291 |k 0/60000/ |p 3 | ||
| 998 | |g 136184626 |a Chronopoulos, Argyrios |m 136184626:Chronopoulos, Argyrios |p 1 |x j | ||
| 999 | |a KXP-PPN1935171062 |e 4767083923 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"given":"Argyrios","role":"aut","family":"Chronopoulos","display":"Chronopoulos, Argyrios"},{"display":"Vidal-Oliver, Lourdes","family":"Vidal-Oliver","role":"aut","given":"Lourdes"},{"family":"Sas","display":"Sas, Lea K.","role":"aut","given":"Lea K."},{"role":"aut","given":"Jakob","display":"Holzwarth, Jakob","family":"Holzwarth"},{"family":"Schutz","display":"Schutz, James","role":"aut","given":"James"},{"role":"aut","given":"Lars-Olof","display":"Hattenbach, Lars-Olof","family":"Hattenbach"}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"The effect of brolucizumab on diabetic macular edema and ischemia; a real-world analysisEuropean journal of ophthalmology","title":[{"title_sort":"European journal of ophthalmology","subtitle":"EJO","title":"European journal of ophthalmology"}],"origin":[{"publisher":"Sage Publishing ; Wichtig","dateIssuedKey":"1991","dateIssuedDisp":"1991-","publisherPlace":"Thousand Oaks, CA ; Milano"}],"note":["Gesehen am 28.02.2020"],"pubHistory":["1.1991 -"],"id":{"issn":["1724-6016"],"zdb":["1475018-1"],"eki":["269534601"]},"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["published in association with European Society of Ophthalomology (SOE), Italian Society of Ophthalmology (SOI), European Paediatric Ophthalmological Society (EPOS), European Association for the Study of Diabetes - Eye Complications Study Group (EASD)"]},"recId":"269534601","titleAlt":[{"title":"EJO"}],"part":{"issue":"6","text":"35(2025), 6, Seite 2174-2183","year":"2025","pages":"2174-2183","volume":"35","extent":"10"},"language":["eng"]}],"recId":"1935171062","name":{"displayForm":["Argyrios Chronopoulos, Lourdes Vidal-Oliver, Lea K. Sas, Jakob W. Holzwarth, James Schutz and Lars-Olof Hattenbach"]},"physDesc":[{"extent":"10 S.","noteIll":"Illustrationen"}],"id":{"eki":["1935171062"],"doi":["10.1177/11206721251340436"]},"note":["Gesehen am 02.09.2025"],"origin":[{"dateIssuedDisp":"May 21, 2025","dateIssuedKey":"2025"}],"title":[{"title":"The effect of brolucizumab on diabetic macular edema and ischemia; a real-world analysis","title_sort":"effect of brolucizumab on diabetic macular edema and ischemia; a real-world analysis"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a CHRONOPOULEFFECTOFBR2120 | ||